Loading...
01/11 03:32
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
System-wide sales $129.6 million, up 2.6% year-over-year. The increase is attributed to the company's efforts to improve profitability and strengthen its digital marketing and brand campaigns.
Comp sales for all clinics opened 13 months Up 1.4% year-over-year. The increase was lower than expected due to macroeconomic headwinds and lower new patient counts, despite stable attrition and better conversions.
Revenue from continuing operations Increased 5% year-over-year to $13.3 million. This growth was mainly due to a greater number of franchised clinics in operation.
Consolidated adjusted EBITDA Grew to $3.2 million, up 52% year-over-year. The improvement is attributed to corporate cost reduction efforts and refranchising initiatives.
Unrestricted cash and equivalents $30 million as of June 30, 2025, up from $25.1 million at the end of last year. The increase was driven by proceeds from the sale of clinics and disciplined capital allocation.
Net income $93,000 compared to a net loss of $3.6 million in the same period last year. The improvement is due to refranchising efforts and cost reduction measures.
Net loss from continuing operations Improved by $720,000 to $990,000, or $0.06 per basic share, from a net loss of $1.7 million, or $0.11 per basic share, in the same period last year. The improvement is attributed to refranchising and cost reduction efforts.
Depreciation and amortization expenses Increased 18% year-over-year to $402,000. The increase was mainly due to the development of software made available for use in the first half of 2025.
Mobile App Launch: The company launched a mobile app beta in June, which became generally available in July. Approximately 10% of active patients are already using the app. Future updates will include personalized information and gamification features to enhance patient engagement.
Refranchising Efforts: The company refranchised 37 clinics in Q2 2025, reducing corporate clinics from 13% to 8% of the portfolio. Notable transactions include selling 31 corporate clinics in Arizona and New Mexico for $11.1 million and acquiring regional developer rights in the Northwest region for $2.8 million. This region includes 46 existing franchise clinics and plans for 30 new sites.
Profitability Initiatives: The company is focusing on enhancing brand campaigns, digital marketing, dynamic revenue management, and patient-facing technology to improve profitability. A new pricing strategy with smaller, frequent price increases and a new Kickstart plan for supplemental adjustments were introduced.
Financial Performance: System-wide sales increased by 2.6% to $129.6 million, and adjusted EBITDA grew by 52% to $3.2 million compared to Q2 2024. Revenue from continuing operations rose by 5% to $13.3 million.
Strategic Shift to Pure-Play Franchisor: The company is transitioning to a pure-play franchisor model, focusing on refranchising corporate clinics and reducing general and administrative expenses. This shift is expected to increase franchise royalties and fees while improving cash flow.
Financial Restatements: The company announced the need to restate previously issued financial statements for 2024 and Q1 2025 due to material errors in valuation methodology. This could impact investor confidence and create regulatory scrutiny.
Macroeconomic Headwinds: Lower new patient counts and softer sales trends were attributed to macroeconomic challenges, which could continue to impact revenue growth and profitability.
Refranchising Risks: The transition to a pure-play franchisor involves selling corporate clinics to franchisees. While this strategy aims to improve profitability, it carries risks such as potential operational disruptions and reliance on franchisee performance.
Marketing and Patient Acquisition Challenges: The company is pivoting its marketing strategy to focus on pain relief rather than general wellness. However, brand awareness campaigns take time to yield results, and lower new patient counts remain a concern.
Regulatory and Compliance Risks: The company faces risks related to compliance with financial reporting standards, as evidenced by the need for financial restatements.
Clinic Closures: The closure of six franchise clinics and three company-owned clinics in Q2 2025 could indicate operational challenges or underperforming locations.
Revenue Growth Uncertainty: Revised 2025 guidance reflects lower expectations for system-wide sales and comp sales growth, signaling potential challenges in achieving financial targets.
Technology Adoption Risks: The rollout of a new mobile app aims to enhance patient experience, but adoption rates and the effectiveness of the app in extending patient lifetime value remain uncertain.
System-wide sales guidance: Revised to a range of $530 million to $550 million for 2025, down from the prior guidance of $550 million to $570 million.
Comp sales growth: Expected to increase in the low single-digit range, revised from the prior guidance of mid-single-digit growth.
Consolidated adjusted EBITDA: Guidance increased to a range of $10.8 million to $11.8 million, up from the prior guidance of $10 million to $11.5 million.
New franchise clinic openings: Expected to range from 30 to 35 in 2025, compared to 57 in 2024.
Refranchising impact: As clinics shift from corporate-owned to franchise, franchise royalties and fees will increase, unallocated G&A expenses will be rationalized, and cash position will improve.
Marketing strategy: Pivoting to a pain relief-focused brand campaign to drive patient acquisition and improve long-term system-wide sales.
Dynamic revenue management: Implementing more frequent, smaller price increases and introducing new plans like the Kickstart plan to optimize pricing and patient value.
Patient-facing technology: Launched a mobile app to enhance patient experience and extend lifetime value, with future updates planned to include personalized features and gamification.
Long-term strategy: Plans to enter the next phase, Joint 3.0, in approximately 12 months, focusing on new revenue streams, additional sales channels, and growth in new markets.
Stock Repurchase Program: In June, the Board authorized a stock repurchase program under which the company may repurchase up to $5 million of our outstanding common stock through June 2027. This buyback reflects the Board's confidence in the company's long-term strategy, refranchising program, and projected cash flow generation.
The earnings call presents strong financial performance with improved net income, EBITDA, and revenue growth. The strategic shift towards refranchising and pricing adjustments, alongside a new marketing focus, is promising. Despite some uncertainties in refranchising timelines, management's confidence and strategic initiatives, such as the app launch and marketing strategy, suggest a positive outlook. Analysts seem cautiously optimistic, with concerns mainly around refranchising timing and pricing strategies, but these are being actively addressed. Overall, the company's strategic direction and operational improvements indicate a likely positive stock reaction.
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
The earnings call presents a mixed picture. Financial performance shows improvement in EPS and revenue, but challenges like economic headwinds, strained franchisee relationships, and increased costs persist. While guidance suggests growth, risks such as inflation and patient retention issues temper optimism. The Q&A reveals some analyst concerns, especially around consumer behavior and unclear management responses. The refranchising strategy and potential stock repurchase are positives, but the lack of guidance on SG&A reductions and technology lags are negatives. Overall, the sentiment is neutral with no strong catalysts for significant stock movement.
The earnings call presents a mixed picture. Financial performance shows some positive trends, such as increased revenue and improved net income, but also highlights challenges like increased operational costs and declining EBITDA. The Q&A section reveals concerns about consumer behavior and retention issues, while management's lack of clear guidance on key metrics adds uncertainty. The refranchising strategy and marketing efforts are positive, but economic headwinds and market competition remain concerns. Overall, these factors suggest a neutral sentiment with potential for slight positive or negative fluctuations.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
